Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (171-180 of 464) with videos related to

Pageof 47
Sort By:
Journal of Clinical Hypertension (Greenwich, Conn.)|January 29, 2011
Barriers to blood pressure control: a STITCH substudySigrid A E Nelson, George K Dresser, Margaret K Vandervoort, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 16, 2025
Factors associated with response to filgotinib and the prognostic power of faecal calprotectin for ulcerative colitis in the phase 2b/3 SELECTION trialEdouard Louis, Stefan Schreiber, Tadakazu Hisamatsu, et al.
Inflammatory Bowel Diseases|February 21, 2018
Infliximab for Crohn's Disease: More Than 13 Years of Real-world ExperienceGary R Lichtenstein, Brian G Feagan, Russell D Cohen, et al.
The American Journal of Gastroenterology|May 13, 2015
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-AnalysisMahmoud H Mosli, Guangyong Zou, Sushil K Garg, et al.
Journal of Crohn'S & Colitis|February 9, 2023
Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION TrialStefan Schreiber, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint studyBrian G Feagan, William J Sandborn, Silvio Danese, et al.
The Cochrane Database of Systematic Reviews|May 16, 2020
Adalimumab for maintenance of remission in Crohn's diseaseCassandra M Townsend, Tran M Nguyen, Jeremy Cepek, et al.
Inflammatory Bowel Diseases|May 17, 2014
A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future researchMark A Samaan, Mahmoud H Mosli, William J Sandborn, et al.
Expert Review of Clinical Pharmacology|March 5, 2024
Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitisGeert D'Haens, Maria Rosario, Daniel Polhamus, et al.
Therapeutic Advances in Gastroenterology|May 28, 2026
A decade of clinical data with vedolizumab: the past, present, and futureVipul Jairath, Alessandro Armuzzi, Christian Agboton, et al.
Pageof 47

Showing results (171-180 of 464) with videos related to

Sort By:
Pageof 47
Journal of Clinical Hypertension (Greenwich, Conn.)|January 29, 2011
Barriers to blood pressure control: a STITCH substudySigrid A E Nelson, George K Dresser, Margaret K Vandervoort, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 16, 2025
Factors associated with response to filgotinib and the prognostic power of faecal calprotectin for ulcerative colitis in the phase 2b/3 SELECTION trialEdouard Louis, Stefan Schreiber, Tadakazu Hisamatsu, et al.
Inflammatory Bowel Diseases|February 21, 2018
Infliximab for Crohn's Disease: More Than 13 Years of Real-world ExperienceGary R Lichtenstein, Brian G Feagan, Russell D Cohen, et al.
The American Journal of Gastroenterology|May 13, 2015
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-AnalysisMahmoud H Mosli, Guangyong Zou, Sushil K Garg, et al.
Journal of Crohn'S & Colitis|February 9, 2023
Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION TrialStefan Schreiber, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint studyBrian G Feagan, William J Sandborn, Silvio Danese, et al.
The Cochrane Database of Systematic Reviews|May 16, 2020
Adalimumab for maintenance of remission in Crohn's diseaseCassandra M Townsend, Tran M Nguyen, Jeremy Cepek, et al.
Inflammatory Bowel Diseases|May 17, 2014
A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future researchMark A Samaan, Mahmoud H Mosli, William J Sandborn, et al.
Expert Review of Clinical Pharmacology|March 5, 2024
Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitisGeert D'Haens, Maria Rosario, Daniel Polhamus, et al.
Therapeutic Advances in Gastroenterology|May 28, 2026
A decade of clinical data with vedolizumab: the past, present, and futureVipul Jairath, Alessandro Armuzzi, Christian Agboton, et al.
Pageof 47